SCHEMBL24470685

SCHEMBL24470685

CCOC(=O)c1c(C)oc2ccc(O)c(C#N)c12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.60
LMNA P02545 2/20 0.55
GAA P10253 2/20 0.52
MAPT P10636 4/20 0.50
ALOX15 P16050 2/20 0.50
HSD17B10 Q99714 1/20 0.50
PTGS2 P35354 5/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 4/20 0.45
KMT2A Q03164 2/20 0.45
HIF1A Q16665 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29630224 0.80 TSHR (0.64) TSHRLMNAGAAMAPTALOX15
SCHEMBL24470880 0.80 TSHR (0.64) TSHRLMNAGAAMAPTALOX15
SCHEMBL11822916 0.80 TSHR (0.64) TSHRLMNAGAAMAPTALOX15
SCHEMBL24470696 0.80 TSHR (0.67) TSHRLMNAGAAMAPTALOX15
SCHEMBL24470679 0.78 ALOX15 (0.51) TSHRGAAALOX15PTGS2ALDH1A1
SCHEMBL29630204 0.78 ALOX15 (0.51) TSHRGAAALOX15PTGS2ALDH1A1
SCHEMBL17918886 0.76 MAPT (0.65) TSHRLMNAGAAMAPTALOX15
SCHEMBL29096004 0.74 TSHR (0.40) TSHRLMNAGAAMAPTALOX15
SCHEMBL29630214 0.74 TSHR (0.40) TSHRLMNAGAAMAPTALOX15
SCHEMBL24470716 0.73 MAPT (0.52) TSHRLMNAGAAMAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
EP-4259613-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2023-10-18 EP disclosed
CN-116761796-A Aryl derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2023-09-15 CN disclosed
CN-116745283-A Heterocyclic derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2023-09-12 CN disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 TSHR 3289/4885LMNA 3056/4885GAA 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.